Raloxifene (RLX) hydrochloride is the first medication from the selective estrogen-receptor modulators family to be licensed by the US Food and Drug Administration as a preventative and therapeutic agent for osteoporosis in postmenopausal women and for the prevention of breast malignant tumors (O’Donnell et al., 2014; FDA Raloxifene Breast Cancer, 2022; National Cancer Institute, 2022). The gene discussed is ESR1; the disease is breast cancer.